A Phase 3 interventional study of efpeglenatide (SAR439977) and placebo in Type 2 Diabetes Mellitus, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 54 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-18.
Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited — 2 open to participants now, 2 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Hanmi Pharmaceutical Company Limited.
Among the 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited, this one has the largest enrollment, is one of 2 that started in 2017, is one of 2 in phase 3, and was the 7th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited are open now, in 2 countries. Recruiting first, the newest first:
Hanmi Pharmaceutical Company Limited · Sites in United States
Ages 18–75
Hanmi Pharmaceutical Company Limited · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 406 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 10 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
2 of the studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07379333Phase 3Hanmi Pharmaceutical Company LimitedA Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin | 2027-11 |
| NCT07527650Hanmi Pharmaceutical Company LimitedStudy to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with T2DM (Type 2 Diabetes Mellitus) inadequately controlled with diet and exercise.
Secondary Objectives:
Study duration per participant is approximately 65 weeks, including a 3-week screening period, 30 weeks core treatment period, 26 weeks extension treatment period, and 6 weeks safety follow up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Efpeglenatide low dose (Prefilled syringe) administered once weekly for 56 weeks
Drug: efpeglenatide (SAR439977)
Efpeglenatide middle dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
Drug: efpeglenatide (SAR439977)
Efpeglenatide high dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
Drug: efpeglenatide (SAR439977)
Matching placebo (Prefilled syringe) administered once weekly for 56 weeks
Drug: placebo
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Change in Glycated Hemoglobin (HbA1c) (%)
Change from Baseline to Week 30 in HbA1c
Time frame: Baseline to Week 30
Change in HbA1c (%)
Change from Baseline to Week 56 in HbA1c
Time frame: Baseline to Week 56
Change in Fasting Plasma Glucose (FPG)
Change from Baseline to Week 30 in FPG
Time frame: Baseline to Week 30
HbA1c <7%
Number of participants with HbA1c \<7.0% at Week 30
Time frame: Week 30
Change in Body Weight at Week 30
Change from Baseline to Week 30 in body weight
Time frame: Baseline to Week 30
Change in Body Weight at Week 56
Change from Baseline to Week 56 in body weight
Time frame: Baseline to Week 56
Hypoglycemic Participants
Number of participants with at least 1 hypoglycemic event during treatment period
Time frame: Baseline to Week 56
Hypoglycemic Events
Number of hypoglycemic events
Time frame: Baseline to Week 56
Treatment Emergent Adverse Events (TEAEs)
Number of participants with TEAEs
Time frame: Baseline to Week 56
| Milestone | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Started | 102 | 100 | 101 | 103 |
| Completed | 80 | 81 | 77 | 81 |
| Not completed | 22 | 19 | 24 | 22 |
| Withdrew: Protocol violation | 1 | 1 | 1 | 0 |
| Withdrew: Other: not related to covid-19 | 2 | 2 | 2 | 0 |
| Withdrew: Adverse event | 0 | 4 | 2 | 3 |
| Withdrew: Withdrawal by subject | 19 | 12 | 19 | 19 |
| Milestone | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Started | 80 | 81 | 77 | 81 |
| Completed | 75 | 78 | 73 | 67 |
| Not completed | 5 | 3 | 4 | 14 |
| Withdrew: Protocol violation | 2 | 0 | 0 | 0 |
| Withdrew: Other: not related to covid-19 | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 3 | 3 | 12 |
Change from Baseline to Week 30 in HbA1c
| HbA1c (%) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Change in Glycated Hemoglobin (HbA1c) (%) | -0.46 ± 1.16 | -1.14 ± 0.96 | -1.48 ± 1.01 | -1.59 ± 1.04 |
Change from Baseline to Week 56 in HbA1c
| HbA1c (%) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Change in HbA1c (%) | -0.52 ± 1.18 | -1.18 ± 0.79 | -1.51 ± 0.99 | -1.51 ± 0.18 |
Change from Baseline to Week 30 in FPG
| FPG (mmol/L) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Change in Fasting Plasma Glucose (FPG) | 8.59 ± 2.13 | -0.87 ± 3.27 | 6.84 ± 1.57 | 6.55 ± 1.30 |
Number of participants with HbA1c \<7.0% at Week 30
| Participants | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| HbA1c <7% | 26 | 60 | 66 | 76 |
Change from Baseline to Week 30 in body weight
| kg | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Change in Body Weight at Week 30 | -1.35 ± 3.15 | -1.01 ± 3.66 | -3.34 ± 4.19 | -3.19 ± 4.77 |
Change from Baseline to Week 56 in body weight
| kg | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Change in Body Weight at Week 56 | -1.26 ± 4.19 | -0.94 ± 4.96 | -3.24 ± 6.42 | -1.82 ± 5.52 |
Number of participants with at least 1 hypoglycemic event during treatment period
| Participants | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Hypoglycemic Participants | 2 | 10 | 14 | 14 |
Number of hypoglycemic events
| Number of events | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Hypoglycemic Events | 2 | 10 | 14 | 14 |
Number of participants with TEAEs
| Number of Treatment Emergent AEs | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Treatment Emergent Adverse Events (TEAEs) | 79 | 80 | 79 | 83 |
Collected over All Adverse Events (AEs), Serious AEs (SAEs), Adverse Events of Special Interest (AESIs) and AEs requiring specific monitoring were collected from the date of signing the Informed Consent Form (ICF) until the end of the study, defined by the protocol for that participant as Week 62.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/102 (0%) | 9/102 (8.8%) | 70/102 (68.6%) |
| Efpeglenatide 2 mg | 0/102 (0%) | 11/102 (10.8%) | 69/102 (67.6%) |
| Efpeglenatide 4 mg | 0/103 (0%) | 6/103 (5.8%) | 73/103 (70.9%) |
| Efpeglenatide 6 mg | 1/99 (1%) | 6/99 (6.1%) | 77/99 (77.8%) |
| Event | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| CystitisInfections and infestations | 0/102 | 0/102 | 0/103 | 1/99 |
| EpiglottitisInfections and infestations | 0/102 | 0/102 | 0/103 | 1/99 |
| Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/102 | 0/102 | 0/103 | 1/99 |
| Laryngeal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/102 | 0/102 | 0/103 | 1/99 |
| Vertebral artery stenosisNervous system disorders | 0/102 | 0/102 | 0/103 | 1/99 |
| Ventricular tachycardiaCardiac disorders | 0/102 | 0/102 | 0/103 | 1/99 |
| Myocardial infarctionCardiac disorders | 1/102 | 0/102 | 0/103 | 1/99 |
| GastroenteritisInfections and infestations | 0/102 | 1/102 | 0/103 | 0/99 |
| Meningitis viralInfections and infestations | 1/102 | 0/102 | 0/103 | 0/99 |
| Benign ovarian tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/102 | 1/102 | 0/103 | 0/99 |
| Event | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 9/102 | 9/102 | 17/103 | 25/99 |
| NauseaGastrointestinal disorders | 2/102 | 6/102 | 15/103 | 22/99 |
| ConstipationGastrointestinal disorders | 6/102 | 9/102 | 14/103 | 16/99 |
| HeadacheNervous system disorders | 7/102 | 6/102 | 10/103 | 15/99 |
| DyspepsiaGastrointestinal disorders | 2/102 | 5/102 | 7/103 | 12/99 |
| NasopharyngitisInfections and infestations | 8/102 | 10/102 | 7/103 | 11/99 |
| Injection site painGeneral disorders | 6/102 | 9/102 | 11/103 | 11/99 |
| Decreased appetiteMetabolism and nutrition disorders | 2/102 | 2/102 | 11/103 | 8/99 |
| DizzinessNervous system disorders | 6/102 | 2/102 | 10/103 | 6/99 |
| VomitingGastrointestinal disorders | 0/102 | 3/102 | 8/103 | 9/99 |
| Age, Customized(Participants) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg | Total |
|---|---|---|---|---|---|
| <50 | 22 | 21 | 30 | 21 | 94 |
| ≥50 and <65 | 43 | 46 | 44 | 44 | 177 |
| ≥65 and <75 | 26 | 28 | 20 | 31 | 105 |
| ≥75 | 11 | 5 | 7 | 7 | 30 |
| Sex: Female, Male(Participants) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg | Total |
|---|---|---|---|---|---|
| Female | 51 | 45 | 49 | 42 | 187 |
| Male | 51 | 55 | 52 | 61 | 219 |
| Race/Ethnicity, Customized(Participants) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg | Total |
|---|---|---|---|---|---|
| Race : White | 90 | 93 | 86 | 92 | 361 |
| Race : Black or African American | 10 | 6 | 13 | 8 | 37 |
| Race : Asian | 2 | 0 | 1 | 2 | 5 |
| Race : Other | 0 | 0 | 1 | 1 | 2 |
| Race : Multiple | 0 | 1 | 0 | 0 | 1 |
| Ethnicity : Hispanic or Latino | 20 | 20 | 25 | 21 | 86 |
| Ethnicity : Not Hispanic or Latino | 82 | 80 | 76 | 82 | 320 |
| Region of Enrollment(participants) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg | Total |
|---|---|---|---|---|---|
| North America | 54 | 53 | 57 | 58 | 222 |
| Europe | 48 | 47 | 44 | 45 | 184 |
| Screening HbA1c(%) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg | Total |
|---|---|---|---|---|---|
| Mean | 7.98 ± 0.85 | 8.03 ± 0.75 | 8.14 ± 0.93 | 8.07 ± 0.91 | 8.05 ± 0.87 |
| Baseline BMI(kg/m²) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg | Total |
|---|---|---|---|---|---|
| Mean | 34.8 ± 7.1 | 34.4 ± 6.4 | 33.8 ± 6.6 | 33.8 ± 6.9 | 34.2 ± 6.8 |
| Baseline BMI category(Participants) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg | Total |
|---|---|---|---|---|---|
| <30 | 28 | 28 | 28 | 28 | 112 |
| ≥30 and <40 | 52 | 53 | 58 | 60 | 223 |
| ≥40 | 22 | 19 | 15 | 14 | 70 |
| Unknown | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Jan 2020, 25 months.
Results were first posted in Jan 2022, 1 year 11 months after primary completion. A results delay was requested in Jan 2021.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 25 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efpeglenatide
Hanmi Pharmaceutical Company Limited →